These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32038227)

  • 1. Antiarrhythmic Properties of Ranolazine: Inhibition of Atrial Fibrillation Associated TASK-1 Potassium Channels.
    Ratte A; Wiedmann F; Kraft M; Katus HA; Schmidt C
    Front Pharmacol; 2019; 10():1367. PubMed ID: 32038227
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.
    Wiedmann F; Beyersdorf C; Zhou X; Büscher A; Kraft M; Nietfeld J; Walz TP; Unger LA; Loewe A; Schmack B; Ruhparwar A; Karck M; Thomas D; Borggrefe M; Seemann G; Katus HA; Schmidt C
    J Am Heart Assoc; 2020 May; 9(10):e015751. PubMed ID: 32390491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant--comparison with flecainide.
    Seyler C; Li J; Schweizer PA; Katus HA; Thomas D
    Eur J Pharmacol; 2014 Feb; 724():51-7. PubMed ID: 24374008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pH-dependent inhibition of K₂P3.1 prolongs atrial refractoriness in whole hearts.
    Skarsfeldt MA; Jepps TA; Bomholtz SH; Abildgaard L; Sørensen US; Gregers E; Svendsen JH; Diness JG; Grunnet M; Schmitt N; Olesen SP; Bentzen BH
    Pflugers Arch; 2016 Apr; 468(4):643-54. PubMed ID: 26729267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial fibrillation and heart failure-associated remodeling of two-pore-domain potassium (K
    Wiedmann F; Schulte JS; Gomes B; Zafeiriou MP; Ratte A; Rathjens F; Fehrmann E; Scholz B; Voigt N; Müller FU; Thomas D; Katus HA; Schmidt C
    Basic Res Cardiol; 2018 Jun; 113(4):27. PubMed ID: 29881975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the A293 (AVE1231) Binding Site in the Cardiac Two-Pore-Domain Potassium Channel TASK-1: a Common Low Affinity Antiarrhythmic Drug Binding Site.
    Wiedmann F; Kiper AK; Bedoya M; Ratte A; Rinné S; Kraft M; Waibel M; Anad P; Wenzel W; González W; Katus HA; Decher N; Schmidt C
    Cell Physiol Biochem; 2019; 52(5):1223-1235. PubMed ID: 31001961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Ablation of TASK-1 (Tandem of P Domains in a Weak Inward Rectifying K
    Schmidt C; Wiedmann F; Beyersdorf C; Zhao Z; El-Battrawy I; Lan H; Szabo G; Li X; Lang S; Korkmaz-Icöz S; Rapti K; Jungmann A; Ratte A; Müller OJ; Karck M; Seemann G; Akin I; Borggrefe M; Zhou XB; Katus HA; Thomas D
    Circ Arrhythm Electrophysiol; 2019 Sep; 12(9):e007465. PubMed ID: 31514528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cloning, functional characterization, and remodeling of K2P3.1 (TASK-1) potassium channels in a porcine model of atrial fibrillation and heart failure.
    Schmidt C; Wiedmann F; Langer C; Tristram F; Anand P; Wenzel W; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
    Heart Rhythm; 2014 Oct; 11(10):1798-805. PubMed ID: 24952150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy.
    Schmidt C; Wiedmann F; Zhou XB; Heijman J; Voigt N; Ratte A; Lang S; Kallenberger SM; Campana C; Weymann A; De Simone R; Szabo G; Ruhparwar A; Kallenbach K; Karck M; Ehrlich JR; Baczkó I; Borggrefe M; Ravens U; Dobrev D; Katus HA; Thomas D
    Eur Heart J; 2017 Jun; 38(22):1764-1774. PubMed ID: 28057773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channels.
    Schmidt C; Wiedmann F; Schweizer PA; Becker R; Katus HA; Thomas D
    Eur J Pharmacol; 2013 Dec; 721(1-3):237-48. PubMed ID: 24070813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Anti-arrhythmic Effects in Human Atria with Combined Use of Sodium Blockers and Acacetin.
    Ni H; Whittaker DG; Wang W; Giles WR; Narayan SM; Zhang H
    Front Physiol; 2017; 8():946. PubMed ID: 29218016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variation in the two-pore domain potassium channel, TASK-1, may contribute to an atrial substrate for arrhythmogenesis.
    Liang B; Soka M; Christensen AH; Olesen MS; Larsen AP; Knop FK; Wang F; Nielsen JB; Andersen MN; Humphreys D; Mann SA; Huttner IG; Vandenberg JI; Svendsen JH; Haunsø S; Preiss T; Seebohm G; Olesen SP; Schmitt N; Fatkin D
    J Mol Cell Cardiol; 2014 Feb; 67():69-76. PubMed ID: 24374141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiological effects of ranolazine in a goat model of lone atrial fibrillation.
    Opačić D; van Hunnik A; Zeemering S; Dhalla A; Belardinelli L; Schotten U; Verheule S
    Heart Rhythm; 2021 Apr; 18(4):615-622. PubMed ID: 33232809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Targets for Old Drugs: Cardiac Glycosides Inhibit Atrial-Specific K
    Schmidt C; Wiedmann F; Gaubatz AR; Ratte A; Katus HA; Thomas D
    J Pharmacol Exp Ther; 2018 Jun; 365(3):614-623. PubMed ID: 29643254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vernakalant activates human cardiac K(2P)17.1 background K(+) channels.
    Seyler C; Schweizer PA; Zitron E; Katus HA; Thomas D
    Biochem Biophys Res Commun; 2014 Aug; 451(3):415-20. PubMed ID: 25108155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of IKr potentiates development of atrial-selective INa block leading to effective suppression of atrial fibrillation.
    Burashnikov A; Belardinelli L; Antzelevitch C
    Heart Rhythm; 2015 Apr; 12(4):836-44. PubMed ID: 25546810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic antiarrhythmic effect of combining inhibition of Ca²⁺-activated K⁺ (SK) channels and voltage-gated Na⁺ channels in an isolated heart model of atrial fibrillation.
    Kirchhoff JE; Diness JG; Sheykhzade M; Grunnet M; Jespersen T
    Heart Rhythm; 2015 Feb; 12(2):409-18. PubMed ID: 25496982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potassium Channel Blockade Enhances Atrial Fibrillation-Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade.
    Aguilar M; Xiong F; Qi XY; Comtois P; Nattel S
    Circulation; 2015 Dec; 132(23):2203-11. PubMed ID: 26499964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiarrhythmic properties of ranolazine: A review of the current evidence.
    Gupta T; Khera S; Kolte D; Aronow WS; Iwai S
    Int J Cardiol; 2015; 187():66-74. PubMed ID: 25828315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.
    Frommeyer G; Milberg P; Uphaus T; Kaiser D; Kaese S; Breithardt G; Eckardt L
    Cardiovasc Ther; 2013 Dec; 31(6):e63-71. PubMed ID: 23647657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.